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Objective: This retrospective study was designed to detect occult microme- 
tastases in the lymph nodes with the use of monoclonal anti-cytokeratin 
reagent, which is specific for epithelial cells but not for lymphocytes or 
plasmacytes, as well as to assess the relationship between the presence of 
occult micrometastases in the lymph nodes and an early relapse in patients 
with stage I non-small-cell ung cancer. Methods: The paratfin-embedded 
sections of 973 regional lymph nodes from 44 patients with stage I 
non-small-cell lung cancer were studied. We used CAM-5.2 as the primary 
monoclonal anti-cytokeratin reagent and an indirect staining technique 
with the streptavidin-biotin-peroxidase complex method. Results: We iden- 
tified cytokeratin-positive c lls in 31 (70.5%) of 44 patients and in 91 (9.4%) 
of the 973 lymph nodes. Of these 31 patients with cytokeratin-positive c lls, 
19 and 12 were restaged as having N1 and N2 disease, respectively. Thirteen 
patients had recurrent disease at 17 sites during the follow-up. Two of these 
recurrences were in the mediastinal nodes and the other 15 occurred at 
distant organs. Twelve of the 13 patients had micrometastatic disease in the 
regional lymph nodes. Disease-free survival duration was significantly 
shorter in the patients with micrometastases in the mediastinal lymph 
nodes than in patients with node-negative disease (p = 0.004). The 
independence of this prognostic significance was demonstrated by a 
multivariate analysis. Conclusion: These findings indicate that the detection 
of occult micrometastases in the mediastinal lymph nodes with monoclonal 
antibodies to cytokeratin can thus be used to predict an early relapse in 
patients with stage I non-small-cell ung cancer. (J Thorac Cardiovasc Surg 
1997;114:535-43) 
T he presence of lymph node metastases is an important prognostic factor in primary lung can- 
cer. Even in patients with stage I non-small-cell lung 
cancer (NSCLC) who have no demonstrable metas- 
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tasis to the regional ymph nodes, recurrent disease 
develops within the early interval after operation, 
and the 5-year-survivals are estimated to be about 
64% to 75%. 1'2 This suggests that the pathologic 
stage as determined by conventional hematoxylin- 
eosin (HE) staining may be underestimated and 
thus the occult metastatic stage may remain unde- 
tected. An accurate assessment of the presence and 
absence of tumor cells in the regional ymph nodes 
is therefore critical for making an accurate progno- 
sis for patients with lung cancer. 3-5 
The development of sensitive immunohistochem- 
ical techniques and specific monoclonal antibodies, 
such as keratin, cytokeratin (CK), and BerEp4, have 
increased our capacity to detect small clusters of 
tumor cells in breast and lung cancer or even single 
tumor cells in the lymph nodes that appear to be 
negative on examination of HE-stained slides. 6-9 We 
focused our attention on the epithelial marker, CK, 
which might be effective for detecting micrometas- 
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Table 1. Characteristics of patients with stage I NSCLC and of the control subjects in this study 
Stage I Control subjects 
pT1 NO MO pT2 NO MO pT1 or T2 N1 340 pT1 or T2 N2 MO 
Total 23 21 78 96 
Age, median (yr) 64 71 64 63 
Sex 
Female 13 7 20 31 
Male 10 14 58 65 
Histologic type of cancer 
Adenocarcinoma 19 10 43 58 
Squamous cell carcinoma 3 10 29 28 
Large-cell carcinoma 0 1 6 8 
Adenosquamous carcinoma 0 0 0 2 
Mucoepidermoid carcinoma 1 0 0 0 
tases in the lymph nodes. The family of human CKs 
consists of 19 different polypeptides,  1° and CKs 8 
and 18 were detected in the tumor  cells of both 
adenocarc inoma and squamous cell carc inoma of 
the lung. n The ant i -CK reagent (CAM-5.2) used in 
this study was able to recognize CKs 8 and 18.12 
This retrospective study was thus designed both to 
detect occult micrometastases in the lymph nodes by 
means of a monoclonal  ant i -CK reagent as well as to 
distinguish between the presence of occult microme- 
tastases in the lymph nodes and an early relapse in 
patients with node-negat ive stage I NSCLC. 
Patients, methods, and follow-up 
tn a series of 95 consecutive patients operated on for 
NSCLC at the Department of Surgery II, Faculty of 
Medicine, Kyushu University, between January 1991 and 
December 1992, we studied 44 patients with stage I 
disease (23:T1 NO M0; 21:T2 NO M0) who underwent a
lobectomy combined with a formal mediastinal nd hilar 
node dissection. The stage of the disease was based on the 
TNM classification of the Union Internationale Contre 
Cancer (UICC). 13 The patients consisted of 24 men and 
20 women. The median age of the patients was 66 years, 
with a range from 25 to 78 years. Twenty-nine patients had 
adenocarcinoma, 13 had squamous cell carcinoma, one 
had large-cell carcinoma, and one had mucoepidermoid 
carcinoma. The median number of lymph nodes available 
for examination from each patient was 23 with a range 
from 8 to 45. 
After the operation, the patients were reexamined every 
month for 1 year, once every 2 months for an additional 2
years, once every 3 months for an additional 3 years, and 
thereafter at 6-month intervals. The evaluations included 
a physical examination and chest roentgenograms at each 
visit and computed tomography and a bone scan every 
year. The median follow-up duration of the patients was 
48 months with a range from 7 to 66 months. 
To compare with N factor restaged by CK, we used, as 
a control group, patients with completely resected patho- 
logic T1 or T2 N1 M0 (n = 78) and T1 or T2 N2 M0 (n = 
96) NSCLC determined by conventional HE staining at 
our department from 1975 to 1995. The characteristics of 
the patients according to the T factor of stage I and of the 
control subjects are shown in Table I. 
Immunostaining procedure of CK. Paraffin-embedded 
tissue sections 5 /xm thick were floated onto 0.01% 
lysine-coated slides. We used the primary monoclonal 
antibody to CKs (clone: CAM-5.2, Becton Dickinson 
Immunocytometry S stems, San Jose, Calif.) and an indi- 
rect staining technique and the streptavidin-biotin-perox- 
idase complex method. After blocking endogenous perox- 
idase with hydrogen peroxide, all deparaffinized sections 
were incubated with 0.1% type II trypsin for 20 minutes at 
37°C to reveal the antigenic site. Possible background 
staining was also removed by applying normal rabbit 
serum, diluted 1:10, for 20 minutes at room temperature. 
We applied mouse CK monoclonal antibody overnight at 
4 ° C; then biotinylated secondary antibody and strept- 
avidin with mouseradish peroxidase (Nichirei Corp., To- 
kyo, Japan) were applied for 15 and 10 minutes, respec- 
tively. Next, all slides were counterstained with methyl 
green. To directly compare the effectiveness of immuno- 
histochemical nalyses with the conventional HE method, 
we studied two additional sections consecutive to those 
displaying CK-positive cells. One section was stained by 
routine HE staining, and the other was immunostained 
with CK. The presence of CK-positive cells within the 
body of the lymph nodes was considered to represent 
metastatic tumor cells even if only one single CK-positive 
cell was detected. 
All slides were examined by two independent observers 
in a double blind fashion. 
Statistical analysis. Survival was calculated from the 
date of operation until death or the date of the last 
follow-up (censored). The duration of the disease-free 
survival was measured from the date of operation until the 
first evidence of recurrence from primary NSCLC or the 
last date of follow-up for patients who remained alive and 
disease free (censored); six patients who died of a cause 
other than primary NSCLC without any evidence of 
disease were censored at death. The disease-free interval 
and survival were analyzed according to the Kaplan-Meier 
method and differences in their distribution were evalu- 
ated by means of the log-rank test. l< 15 Ap  value less than 
0.05 was defined as being statistically significant. Cox 
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Fig. 1. A, Section of the lymph node regional to primary lung adenocarcinoma. A single CK-positive tumor 
cell is seen against a background ofbenign lymph nodes cells by means of the strept-avidin-biotin complex 
immunoperoxidase technique with a monoclonal CK antibody and methyl-green counterstaining. B, A 
comparable s ction from the same lymph nodes as depicted in A, stained by HE. No tumor cells are visible 
in this routine preparation. (Original magnifications ×80.) 
proportional hazards models were applied for multivari- 
ate analysis. 16 Data were analyzed with the use of Abacus 
Concepts, Survival Tools for StatView (Abacus Concepts, 
Inc., Berkeley, Calif.). 
Results 
Lymph node micrometastases detected by CK. 
First, we tried to confirm a reactivity of the anti-CK 
monoclonal antibody in the primary lesion of 44 
cases in this study. All cases showed a strong posi- 
tivity with CK immunohistochemistry (not shown). 
We examined a total of 973 lymph nodes from 44 
patients with conventional stage I disease. We thus 
identified CK-positive cells in 25 (5.6%) of the 450 
lymph nodes from patients with T1 NO M0 disease 
and in 66 (12.6%) of the 523 lymph nodes from 
patients with T2 NO M0 disease in whom metastases 
had not been detected by a routine examination of 
HE-stained slides. In positive lymph nodes, either 
single metastatic tumor cells or small clusters of 
such cells were usually present in the subcapsular or 
medullary sinuses and less frequently in the afferent 
lymphatics or in the true lymphoid areas of the node 
(Fig. 1, A and B). 
Among 23 patients with T1 N0 M0 disease, CK- 
positive cells in the lymph nodes of the hilar and 
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Fig. 2. A, The distribution of CK-positive tumor cells in the lymph nodes of T1 disease. B, The distribution 
of CK-positive tumor cells in the lymph nodes of T2 disease. The open squares indicate lymph nodes that 
were not examined, the hatched squares represent he CK-negative lymph nodes, and the closed squares 
denote the CK-positive lymph nodes. The numbers assigned to the regional nodal stations are as follows: 
number 1 indicates the highest mediastinal nodes, number 2 the paratracheal nodes, number 3 the 
pretracheal nodes, number 4 the tracheobronchial ngle nodes, number 5 Botallo's nodes, number 6 the 
paraaortic (ascending aorta) nodes, number 7 the subcarinal nodes, number 8 the paraesophageal nodes, 
number 9 the pulmonary ligament nodes, number 10 the hilar nodes, number 11 the interlobar nodes, and 
number 12 the lobar nodes. 2s 
mediastinal regions were detected in 12 (52.2%) and 
three (13.0%) patients, respectively. Among 21 pa- 
tients with T2 NO M0 disease, cytokeratin-positive 
cells in the lymph nodes of the hilar and mediastinal 
regions were detected in seven (33.3%) and nine 
(42.9%) patients, respectively (Fig. 2, A and B). 
Relationship between recurrence and microme- 
tastasis. Follow-up data were available for at least 3 
years on these patients after the operation. Among 
23 patients with T1 NO M0 disease, four patients had 
recurrence in this period; the sites of recurrence 
included the bone in one, the contralateral ung in 
one, the brain in one, and the mediastinat lymph 
nodes in one. Of the four patients with recurrence, 
three had N1 or N2 disease with micrometastasis in 
the nodes that were undetectable in the routine 
examination of HE staining, but were visible with 
the use of immunohistochemical techniques. Among 
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Fig. 4. The survival curves by the restaged N factor. 
21 patients with T2 NO M0 disease, nine patients 
had recurrence in this period; the sites of recurrence 
were the mediastinal lymph nodes in one, the ipsi- 
lateral lung in two, the contralateral lung in one, the 
bone in three, the brain in three, the liver in two, 
and the skin in one. In the nine patients with 
recurrence, two had N1 disease and seven had N2 
disease with micrometastasis in the lymph nodes. 
Fig. 3 shows the disease-free survival by N factor 
restaged by CK. In patients with NO disease restaged 
by CK (CK-N0), 3-year disease-free survival was 
92.3%. In patients with N1 disease restaged by CK 
(CK-N1), the 1- and 3-year disease-free survivals 
were 94.4% and 77.8%, respectively. In patients with 
N2 disease restaged by CK (CK-N2), the 1- and 
3-year disease-free survivals were 66.7% and 33.3%, 
respectively. The duration of disease-free survival 
was significantly shorter in patients with CK-N2 
disease than in those with CK-N0 and CK-N1 
disease (p = 0.004 and p = 0.008). 
The overall 5-year survival was 64.4% in this 
study. Fig. 4 shows the survival by N factor estaged 
by CK. The 5-year survivals were 83.0% for patients 
with CK-N1 disease and 27.8% for patients with 
5 4 0 Maruyama et al. 
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Fig. 5. A, The survival of patients with pathologic N1 disease and N1 disease restaged by CK. B, The 
survival of patients with pathologic N2 disease and N2 disease restaged by CK. 
CK-N2 disease. The 5-year survival was 90.9% for 
patients with CK-N0 disease, and the difference 
between CK-N0 and CK-N2 disease was significant 
(/9 = 0.036). 
We next compared the patients having CK-N1 
disease with the patients having completely resected 
pathologic T1 or T2 N1 M0 disease (n = 78), and we 
compared the patients having CK-N2 disease with 
those having completely resected pathologic T1 or 
T2 N2 M0 disease (n = 96). Fig. 5, A shows the 
survival both of the patients with pathologic N1 
disease and of those with CK-N1 disease. Survival 
was significantly shorter in the patients with patho- 
logic N1 disease than in the patients with CK-N1 
disease (p < 0.001). Fig. 5, B shows the survival of 
patients with pathologic N2 disease and CK-N2 
disease, and the difference between the two modal- 
ities was not significant. 
Table II demonstrates univariable risk ratios, 95% 
confidence intervals, and p values on early tumor 
relapse rates. It was demonstrated that only micro- 
metastases in the mediastinal lymph nodes were 
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prognostic factors in multivariable models (hazards 
ratio = 8.508; 95% confidence intervals = 1.019, 
71.039; p value = 0.048). 
Discussion 
Up to now, the pathologic staging of cancer has 
been primarily based on an examination of the 
HE-stained nodes. Single tumor cells or small clus- 
ters of tumor cells nestled among the lymphocytes 
and/or sinus histiocytes can be easily overlooked, 
thus leading to a false-negative assessment. Occult 
micrometastases in the lymph nodes have also been 
identified by other investigators using immunohisto- 
chemical techniques inbreast and lung cancer 6-9 and 
by others using molecular biologic techniques in 
colorectal and lung cancer. 17-19 Hayashi and associ- 
ates 18 reported micrometastases in the lymph nodes 
of the patients with eolorectal cancer using the 
mutant allele-specific amplification method, and 
this method was also useful for detecting K-ras 
mutations.17 Betz and coworkers, 19 using the reverse 
transcriptase-polymerase chain reaction method 
targeting pulmonary surfactant apoprotein, re- 
ported detecting micrometastases in the lymph 
nodes of patients with NSCLC. 
This study emphasized the value of immunohisto- 
chemistry in detecting micrometastases in the lymph 
nodes and assessed the relationship between pres- 
ence of micrometastases in the lymph nodes and an 
early relapse in patients with node-negative stage I
NSCLC. 
All types of epithelial tissue, both normal and 
malignant, contain CKs, which form the intermedi- 
ate filament cytoskeleton within the epithelial cell. 
This family of human CKs consists of 19 different 
polypeptides, which have been numbered 1through 
19 by Moll and associates. I° We used CAM-5.2, 
which recognizes CKs 8 and 18, as the monoclonal 
anti-CK reagent in this study. 12 CKs 8 and 18 were 
detected in the tumor cells of both adenocarcinoma 
and squamous cell carcinoma of the lung. 11 There- 
fore this immunohistochemical method can be ef- 
fectively applied to almost all cases of NSCLC. 
Anti-CK reagents have some advantages and disad- 
vantages. The anti-CK reagent is not specific for 
lung cancer cells, and a positive reaction was also 
seen with nontumor cells in the lymph nodes. In 
addition, Traweek, Liu, and Battifora 2° reported 
that variable levels of keratin 8 and 18 gene expres- 
sion were detected by reverse transcriptase-poly- 
merase chain reaction targeting to CK in normal 
lymph nodes. Therefore it remains possible that the 
Table II. Univariate statistics of disease-free 
smvival 
Hazards 95% p 
Variable ratio Confidence interval Value 
Sex 
Male 1.0 
Female 1.858 0.607, 5.684 0.2777 
Age (yr) 
<66 1.0 
->66 1.088 0.365, 3.239 0.8802 
Histologic type of cancer 
Squamous 1.0 
Nonsquamous 0.849 0.261, 2.759 0.7855 
T factor 
T1 1.0 
T2 3.313 1.012, 10.844 0.0477 
N factor restaged by CK 
NO 1.0 
N1 2.738 0.306, 24,504 0.3678 
N2 11.701 1.456, 94,015 0.0207 
detection of occult metastases in lymph nodes with 
this molecular biologic method could be false posi- 
tive. Passlick and associates 9 used monoclonal anti- 
body BerEp4, which is directed against wo epithe- 
lial cell surface glycopolypeptides. 21' 22 The antibody 
does not react with mesenchymal tissue, including 
lymphoid tissue. 21 However, in addition to comparing 
the morphologic and staining similarities of primary 
lesions, the standard cytologic criteria of cell and 
nuclear size, nucleolation, and the nucleus-cytoplasmic 
ratio allowed us to easily distinguish CK-positive tu- 
mor cells from nontumor cells while ruling out a 
false-positive finding of occult metastases in the lymph 
nodes with this immunohistochemical method. 
Even if any doubt remains as to whether a single 
tumor cell or small clusters of tumor cells in the 
lymph nodes by immunohistochemical methods re- 
flect overt clinical metastasis, their presence might 
indicate a poor prognosis. According to many re- 
ports, the 5-year survivals in patients with pathologic 
N1 disease and N2 disease were 39% to 43% and 
14% to 30%, respectively, 2' 3, 23~26 and our results 
correspond with these reports. We compared the 
patients having CK-N1 disease with the patients 
having completely resected pathologic T1 or T2 N1 
M0 disease, and we compared the patients having 
CK-N2 disease with those having completely re- 
sected pathologic T1 or T2 N2 M0 disease. As a 
result, tumor cells in the lymph nodes by immuno- 
histochemical methods reflect overt pathologic me- 
tastases in the patients with CK-N2 disease, but not 
in those with CK-N1 disease. 
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However, regarding the sites of recurrence in this 
study, distant metastases were more frequent han 
local recurrence, and the pattern of metastasis was 
more often hematogenous than lymphogenous. 
Martini and associates 26reported on 114 patients 
with recurrence in 214 patients with stage II lung 
cancer. Ninety patients (79%) had distant metasta- 
ses. As their report indicated, the nodal involvement 
did not necessarily reflect lymphogenous metasta- 
ses, but might be an indicator of hematogenous 
spread. Of 31 patients with CK-detected lymph node 
micrometastases, 19 patients did not have a recur- 
rence. We can be fairly certain that all patients 
underwent complete resections in our study. How- 
ever, systemic micrometastatic spread might have 
occurred in some patients with CK-positive lymph 
nodes disease, especially CK-N2 disease. Pantel and 
associates 27reported the CK immunocytologic de- 
tection of bone marrow micrometastasis in patients 
with NSCLC. The immunohistochemical methods 
with anti-CK reagent may thus be useful for per- 
forming an accurate assessment of the clinical stage. 
Passlick and coworkers 9 previously demonstrated 
that patients with lymph node micrometastases 
showed a significantly shorter disease-free survival 
duration than patients with negative nodes, and 
their findings were confirmed by our present study. 
In addition, we indicated the relationship between 
early recurrence and micrometastases in the medi- 
astinal ymph nodes of patients with stage I NSCLC 
for the first time. We may thus believe that stage I
NSCLC with CK-positive mediastinal lymph nodes 
represents occult advanced isease with potential 
indications for adjuvant herapy. 
We thank Dr. Brian T. Quinn for critical comments on 
the manuscript. 
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